Search Results
Your search for ,twO matches 12461 pages
Showing 651 - 700Novel Formulation Used in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting
In a Chinese phase III trial (PROFIT) reported in Journal of Clinical Oncology, Zhou et al found that mixed-formulation fosrolapitant/palonosetron (HR20013) plus dexamethasone was noninferior to individually dosed fosrolapitant plus palonosetron plus dexamethasone in preventing chemotherapy-induced ...
Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found evidence of efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy and consolidative immunotherapy in patients with locally advanced non–small cell lung cancer...
CBD May Not Reduce Scan-Related Anxiety in Patients With Advanced Breast Cancer
Cannabidiol (CBD) may not significantly change scan-related anxiety compared with placebo in patients with advanced breast cancer but may result in lower overall anxiety levels, according to a recent study published by Nayak et al in JAMA Network Open. Background Anxiety is common among adult...
Managing Comorbidities in Oncology: Practical Strategies for Optimized Patient Care
Cancer care is increasingly complicated by the presence of comorbidities, which affect nearly two-thirds of patients at the time of diagnosis and can influence treatment decisions, participation in clinical trials, and overall outcomes. During 2024 JADPRO Live, M. Edie Brucker, DNP, MPH, ARNP,...
Effectiveness of Multimodal Machine-Learning Model in Predicting Response to Treatment in Breast Cancer Subtype
A machine-learning model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data alone in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6...
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients With ‘Good-Risk’ DCIS Who Forgo Radiation
For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the 2024 San Antonio Breast Cancer Symposium...
Adrienne Waks, MD, on MARGOT/TBCRC052: Phase II Trial in HER2-Positive Breast Cancer
Adrienne Waks, MD, of Dana-Farber Cancer Institute, Boston, discusses the randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab vs paclitaxel/trastuzumab/pertuzumab in patients with stage II-III HER2-positive breast cancer. This trial is being done to determine how well ...
Autologous Stem Cell Transplantation May Not Improve Survival in Patients With MCL and Undetectable Minimal Residual Disease
Researchers have revealed that high-dose chemotherapy followed by autologous stem cell transplantation may not benefit patients with mantle cell lymphoma (MCL) who are in remission following initial treatment, according to new findings presented by Fenske et al at the 2024 American Society of...
Quality of Life Similar Among Patients With Low-Risk DCIS Whether They Received Active Monitoring or Surgery
Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring and those who received upfront treatment reported comparable physical, emotional, and psychological outcomes, according to results from the COMET trial presented at the 2024 San Antonio Breast Cancer Symposium...
Active Monitoring May Be a Viable Option for Some Patients With Low-Risk DCIS
Among patients with hormone receptor–positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar 2-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the...
Bicistronic CAR T-Cell Therapy Achieved Durable Remissions in Children With Relapsed/Refractory B-Cell ALL
A follow-up study investigating the coadministration of CD19- and CD22-targeted chimeric antigen receptor (CAR) T-cell therapy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) found the therapy is safe and effective and achieved durable remissions in these patients, ...
Nivolumab/Ipilimumab vs Chemotherapy With or Without Targeted Agents in MSI-H or dMMR Metastatic Colorectal Cancer
As reported in The New England Journal of Medicine by Andre et al, interim analysis of the phase III CheckMate 8HW trial has shown that nivolumab plus ipilimumab prolonged progression-free survival vs chemotherapy with or without targeted agents in patients with microsatellite instability–high...
Pirtobrutinib May Improve Survival Outcomes in Pretreated Patients With CLL or SLL
Researchers have found that the noncovalent Bruton's tyrosine kinase inhibitor (BTK) pirtobrutinib may offer superior progression-free survival in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to recent findings presented by Sharman et al at the 2024...
Combination of Two Oral Agents May Improve Progression-Free Survival in Patients With Previously Untreated CLL
A combination of the oral drugs acalabrutinib and venetoclax may be more effective at improving progression-free survival and minimizing serious adverse events in patients with previously untreated chronic lymphocytic leukemia (CLL) compared with one of two standard multidrug treatment regimens,...
High-Fiber Diet May Slow Disease Progression to Multiple Myeloma
Recent data suggest that a plant-based diet rich in fiber may help to improve the outlook for people with precursor conditions that can lead to multiple myeloma. The research, which involved a 12-week controlled diet with additional health coaching for 20 patients as well as experiments in mice, is ...
Loncastuximab Tesirine May Improve Outcomes in High-Risk Follicular Lymphoma, Marginal Zone Lymphoma
The antibody loncastuximab tesirine may offer a benefit in patients with high-risk follicular lymphoma and marginal zone lymphoma, according to the findings of two clinical trials presented by Alderuccio et al and Lossos et al at the 2024 American Society of Hematology (ASH) Annual Meeting &...
Rilzabrutinib Found Safe and Effective for Refractory Immune Thrombocytopenia
The experimental drug rilzabrutinib was well tolerated and generated an increase in platelet counts among some adults with immune thrombocytopenia (ITP) who had not experienced lasting improvements with other available ITP treatments, according to the results of a phase III trial. These findings...
Preclinical Findings Show Ketogenic Diet Enhances CAR T-Cell Function, Improves Tumor Control
Findings from a series of studies conducted in mice, human tissues, and healthy volunteers suggest that a ketogenic diet may enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy. The results point to β-hydroxybutyrate (BHB), a substance produced when a ketogenic diet is...
Award Recipients Announced for the 2024 San Antonio Breast Cancer Symposium
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will honor two researchers for their significant contributions to breast cancer research during the 2024 SABCS. 2024 AACR Distinguished Lectureship in Breast Cancer Research ...
Metformin May Impact Immunotherapy in NSCLC
Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity, according to a recently published article in the Journal of the National Cancer Institute.1 The investigators looked at data from two groups of...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Cameroon
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Cameroon. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Understanding How Stigma and Incorrect Physician Assumptions About LGBTQ+ Patients’ Needs Contribute to Medical Mistrust
Over the past decade, ASCO has focused its resources on advancing health equity for sexual and gender minority (SGM) individuals with cancer. In 2017, the Society published a position statement “Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations,” which...
Deciphering the Impact of the 2024 Election on Cancer Care
Two weeks after the 2024 election, the Presidency and 119th Congress are coming into focus, with nearly all races called. Republican Donald Trump was elected President, and Republicans regained control of the U.S. Senate (53–47) and maintained control in the House of Representatives (218–212 at...
Pediatric Cancer Clinical Trial Research Should Include Social Determinants of Health
ASCO is calling for pediatric clinical trials to prioritize health equity and social determinants of health (SDOH) data in future trials to improve cancer treatment and survivorship in patients. In a recent position statement, ASCO addresses the need to include SDOH data collection and intervention ...
The Future of Cancer Care, Part 2
The soaring number of cancer survivors since the National Cancer Act of 1971 was enacted into law provides a snapshot of the profound progress made against cancer over the past half-century: 3 million survivors in the 1970s,1 compared to more than 18 million today, and that number is expected to...
Understanding the Assessment and Treatment of High-Risk Myelofibrosis
At the 2024 JADPRO Live event, which is held annually for advanced practitioners in oncology, high-risk myelofibrosis was a featured topic. “The treatment landscape has developed so much that JADPRO asked us to present our talks on the main stage this year,” said Julie Huynh-Lu, PA-C, Supervisor...
Potential Cancer Vaccine Target Uncovered in E coli Bacteria
Targeting certain bacterial strains linked to cancer with treatments or vaccines may help to reduce the risk of colorectal cancer, urothelial carcinoma, and prostate cancer, according to a novel study published by Mäklin et al in The Lancet Microbiome. Background The bacterium Escherichia coli is...
Prior Authorization Delays May Lead to Severe Consequences for Patients With Cancer
A recent nationwide survey has confirmed that prior authorization may cause treatment delays, abandoned treatments, hospitalizations, and deaths among patients with cancer, according to an executive summary published by the American Society for Radiation Oncology (ASTRO). The findings may reinforce ...
Study Highlights From MD Anderson Researchers
Here are some highlights of clinical trials presented at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center. They include breakthroughs in cancer care, updates in clinical research, and efforts in cancer...
Understanding the Link Between Obesity and Cancer
Worldwide, more than a billion people have obesity—including 650 million adults, 340 million adolescents, and 39 million children1—a rate that has nearly doubled since 1980.2 In the United States alone, about two out of three adults are overweight or have obesity, and one out of three have...
Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit
Adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates in patients with resectable gastric cancer but does not extend overall survival, according to data presented at the European Society for Medical Oncology (ESMO) Congress 20241 and published...
Obecabtagene Autoleucel in Adults With B-Cell ALL
A second-generation chimeric antigen receptor (CAR) T-cell therapy may offer a new option for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), an aggressive blood cancer with few treatment options. Results from the phase Ib/II FELIX trial, published by Roddie et al in ...
Lung Cancer CT Screening May Help to Detect Coronary Artery Disease
Lung cancer screening with low-dose chest computed tomography (CT) may be capable of identifying coronary artery calcium in patients without cardiac symptoms, according to a recent study published by Caires et al in the Canadian Medical Association Journal. Background Lung cancer is currently one...
Ramucirumab/Paclitaxel as Switch Maintenance in Advanced HER2-Negative Gastric/Gastroesophageal Junction Cancer
In an Italian phase III study (ARMANI) reported in The Lancet Oncology, Randon et al found that switch maintenance with ramucirumab/paclitaxel was associated with significantly improved progression-free survival vs continuation of first-line oxaliplatin-based chemotherapy in patients with advanced...
MRD-Guided Chemotherapy Intensification After Induction in Fit Older Patients With AML
As reported in the Journal of Clinical Oncology by Russell et al, the NCRI AML18 trial has shown survival benefit with treatment intensification in fit older patients with measurable residual disease (MRD)-positive response after first induction for acute myeloid leukemia (AML). Study Details In...
Pharmacokinetic Comparison of Aumolertinib, Osimertinib, Gefitinib, and Their Major Metabolites in NSCLC
Researchers may have established an accurate ultraperformance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for comparing the pharmacokinetic properties of three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and their major metabolites in mouse...
Ovarian Cancer 2024: Year-at-a-Glance, Part 2
In this second installment of a two-part discussion about ovarian cancer advances for The ASCO Post Newsreels, Ursula A. Matulonis, MD, and Joyce F. Liu, MD, MPH, discuss low-grade serous ovarian carcinoma and an important recently published study. View part 1 of the program to hear them discuss...
Ovarian Cancer 2024: Year at a Glance, Part 1
Over the past year, several important studies in ovarian cancer have been presented at multiple oncology meetings and published in a number of peer-reviewed publications. In this installment of a two-part discussion for The ASCO Post Newsreels, Ursula A. Matulonis, MD, and Joyce F. Liu, MD, MPH,...
At-Home Testing Kits, Coordinated Outreach May Improve Colorectal Cancer Screening Rates
Researchers have demonstrated that a targeted intervention may increase screening rates in patients who do not adhere to current colorectal cancer screening recommendations, according to a recent study published by Reuland et al in JAMA Network Open. Background Colorectal cancer screening is often...
Peer Support Intervention May Help Improve Psychological Outcomes Among Patients With Cancer in Low-Resource Settings
Researchers have found that the cancer peer support program Stronger Together may provide critical social support to patients with cancer, particularly in low-resource settings in low- and middle-income countries, according to a recent study published by Le et al in JCO Global Oncology. Background...
Prognostic Factors in Limited-Stage SCLC Treated With Escalated Radiotherapy Doses
In a study reported in JAMA Network Open, Farris et al identified prognostic factors in patients with limited-stage small cell lung cancer (SCLC) receiving radiotherapy at two dose schedules in the CALGB 30610–RTOG 0538 trial. Study Details In the trial, 638 patients were randomly assigned between...
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, confirms the benefit for the STRIDE regimen of the monoclonal antibodies durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.1 [The STRIDE regimen consists of a single priming dose of...
T-DXd of Benefit in Patients With Breast Cancer and Brain Metastases
Late-breaking findings from the phase IIIb/IV, open-label DESTINY-Breast12 trial support the use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive metastatic breast cancer and brain metastases who have experienced disease progression on at least...
Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer
For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, was bolstered by the positive overall survival analysis...
Highlights From the ESMO Congress 2024
The European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona featured several groundbreaking trials with the potential to significantly influence clinical practice. These studies highlighted the benefits of new combination immunotherapy strategies and innovative approaches in the...
NCCN Guidelines Expanded to Meet Growing Understanding of Hereditary Risk
The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers.1 “The recently updated NCCN Guidelines for ...
How Functional and Genomic Precision Medicine Are Getting Closer to Matching Each Patient to the Right Therapy
Functional precision medicine—in which information is obtained from direct perturbations of tumor-derived living cells that enable immediate translatable, personalized data to guide patient therapy—has its roots dating back more than 50 years.1 However, advances in two- and three-dimensional...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III -CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
